Spiderwort, a spun out from the Pelling Lab, is a biotech company innovating in cellulose-based tissue scaffolding to treat acute spinal cord injuries.
Spiderwort specializes in the development of transformative biomaterials for repairing and regenerating tissues within the human body.
Spiderwort was founded in 2015 by Charles M. Cuerrier and Andrew Pelling. The company is headquartered in Ottawa, Ontario, Canada.
Spiderwort is transforming biotechnology with a platform of cellulose-based biomaterials that serve as the scaffolds for the regenerative medicine of the future.
Spiderwort's CelluBridge is a proprietary cellulose-based biomaterial that promotes the repair and regeneration of the spinal cord. The CelluJuve™ is a cellulose-based dermal filler that can address different patient use cases including injury recovery and cosmetic enhancement.
Spiderwort is backed by Horizons Ventures, K5 Global, BoxOne Ventures, Capital Angel Network, Break Off Capital, Anges Québec, and others. The company raised $13.2M in Series A round on Jul 12, 2022. This brings Spiderwort's total funding to $16.1M to date.